Alfonso Iorio

Alfonso Iorio's AcademicInfluence.com Rankings

Alfonso Iorio

Engineering

#7470

World Rank

#8846

Historical Rank

Biomedical Engineering

#760

World Rank

#772

Historical Rank

Electrical Engineering

#2338

World Rank

#2446

Historical Rank

Applied Physics

#2599

World Rank

#2640

Historical Rank

engineering Degrees

Download Badge

Engineering

Why Is Alfonso Iorio Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Alfonso Iorio's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Interventions for enhancing medication adherence. (2008) (2134)
Discrimination and Calibration of Clinical Prediction Models: Users’ Guides to the Medical Literature (2017) (713)
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. (2001) (553)
D-dimer testing to determine the duration of anticoagulation therapy. (2006) (527)
Aryl hydrocarbon receptor control of a disease tolerance defence pathway (2014) (502)
Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. (1998) (483)
Guideline for opioid therapy and chronic noncancer pain (2017) (449)
Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients (2015) (437)
Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH) (2012) (379)
Impact of Thrombophilia on Risk of Arterial Ischemic Stroke or Cerebral Sinovenous Thrombosis in Neonates and Children: A Systematic Review and Meta-Analysis of Observational Studies (2010) (363)
The GRADE Working Group clarifies the construct of certainty of evidence. (2017) (335)
Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. (2010) (319)
Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study (2011) (273)
Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma‐derived or recombinant factor VIII concentrates: a systematic review (2010) (272)
Effectiveness of computerized decision support systems linked to electronic health records: a systematic review and meta-analysis. (2014) (256)
Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis (2011) (246)
Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. (2000) (229)
Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient‐level meta‐analysis (2010) (200)
Patient-Level Meta-analysis: Effect of Measurement Timing, Threshold, and Patient Age on Ability of d-Dimer Testing to Assess Recurrence Risk After Unprovoked Venous Thromboembolism (2010) (170)
Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males (2019) (151)
Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta‐analysis of randomized controlled trials (2015) (148)
Low‐molecular‐weight heparin for the long‐term treatment of symptomatic venous thromboembolism: meta‐analysis of the randomized comparisons with oral anticoagulants (2003) (148)
Association of Anticholinergic Burden with Cognitive and Functional Status in a Cohort of Hospitalized Elderly: Comparison of the Anticholinergic Cognitive Burden Scale and Anticholinergic Risk Scale (2013) (147)
Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal A systematic review and meta-analysis (2016) (127)
Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. (2011) (119)
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura (2020) (118)
Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. (2005) (118)
Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. (2009) (117)
Individual participant data meta-analyses compared with meta-analyses based on aggregate data. (2011) (117)
Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. (2006) (112)
COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine (2020) (112)
Use of GRADE for assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks. (2020) (109)
Inhibitor development in haemophilia according to concentrate (2015) (107)
GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence. (2017) (106)
Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation study (2016) (104)
Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting (2010) (102)
Psychosocial aspects of haemophilia: a systematic review of methodologies and findings (2012) (102)
Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopatic deep venous thrombosis. (2001) (95)
Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. (2011) (95)
Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. (2011) (94)
Recommendations for the Management of Intracranial Haemorrhage – Part I: Spontaneous Intracerebral Haemorrhage (2006) (87)
Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis (2013) (87)
Haemophilia Experiences, Results and Opportunities (HERO) Study: survey methodology and population demographics (2014) (86)
Bone mineral density in haemophilia patients (2010) (83)
Development of a Web-Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo): Study Protocol (2016) (82)
ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura (2020) (82)
Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis (2008) (81)
Risk factors for hospital readmission of elderly patients. (2013) (79)
McMaster RARE‐Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome (2018) (78)
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment (2009) (78)
Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data (2015) (72)
Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project (2018) (68)
Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH (2017) (64)
Inhibitor development in previously treated hemophilia A patients: a systematic review, meta‐analysis, and meta‐regression (2013) (62)
Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis (2016) (62)
Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: The extended DACUS study (2011) (61)
Drug–drug interactions in a cohort of hospitalized elderly patients (2013) (61)
Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000–18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database (2020) (60)
Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta‐analysis (2017) (58)
Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors (2012) (57)
Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement (2017) (54)
Prognostic factors for VTE and Bleeding in Hospitalized Medical Patients: a systematic review and meta-analysis. (2020) (54)
Thrombosis in Inherited Fibrinogen Disorders (2017) (52)
Uncertainties in baseline risk estimates and confidence in treatment effects (2012) (51)
Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. (2010) (50)
Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with Behçet's disease and deep vein thrombosis. (2004) (50)
Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A (2015) (50)
Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. (2011) (49)
Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. (2010) (49)
Haemophilia Experiences, Results and Opportunities (HERO) Study: Influence of haemophilia on interpersonal relationships as reported by adults with haemophilia and parents of children with haemophilia (2014) (49)
Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. (2011) (48)
Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. (2015) (48)
The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A (2016) (48)
NHF‐McMaster Guideline on Care Models for Haemophilia Management (2016) (48)
Clotting factor concentrate switching and inhibitor development in hemophilia A. (2012) (47)
Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa (2014) (45)
IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. (2015) (45)
The GRADE evidence-to-decision framework: a report of its testing and application in 15 international guideline panels (2015) (45)
Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. (1995) (44)
Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: Experience in the standard clinical setting (2007) (43)
Systematic reviews experience major limitations in reporting absolute effects. (2016) (43)
The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta‐analysis (2020) (43)
In-hospital death and adverse clinical events in elderly patients according to disease clustering: the REPOSI study. (2010) (42)
Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations (2018) (41)
A Deep Learning Method to Automatically Identify Reports of Scientifically Rigorous Clinical Research from the Biomedical Literature: Comparative Analytic Study (2018) (40)
Pharmacokinetics and the transition to extended half‐life factor concentrates: communication from the SSC of the ISTH (2018) (40)
The World Federation of Hemophilia Annual Global Survey 1999‐2018 (2020) (40)
Emicizumab and thrombosis: The story so far (2019) (40)
Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey. (2014) (39)
A systematic review found that deviations from intention-to-treat are common in randomized trials and systematic reviews. (2017) (38)
Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo) (2016) (38)
In‐hospital death according to dementia diagnosis in acutely ill elderly patients: the REPOSI study (2011) (37)
Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates (2017) (37)
Using pharmacokinetics to individualize hemophilia therapy. (2017) (36)
The good use of plasma. A critical analysis of five international guidelines. (2008) (35)
Intracranial Haemorrhage in Patients on Antithrombotics: Clinical Presentation and Determinants of Outcome in a Prospective Multicentric Study in Italian Emergency Departments (2006) (34)
The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters (2013) (33)
Adverse clinical events and mortality during hospitalization and 3 months after discharge in cognitively impaired elderly patients. (2013) (33)
Comparative pharmacokinetics of two extended half‐life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference? (2019) (33)
Defining certainty of net benefit: a GRADE concept paper (2019) (32)
Hemophilia trials in the twenty‐first century: Defining patient important outcomes (2019) (32)
Switching to extended half‐life products in Canada – preliminary data (2017) (31)
Past, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomes (2018) (31)
The McMaster Optimal Aging Portal: Usability Evaluation of a Unique Evidence-Based Health Information Website (2016) (31)
Authors seldom report the most patient-important outcomes and absolute effect measures in systematic review abstracts. (2017) (31)
Central nervous system bleeding in patients with rare bleeding disorders (2012) (30)
Strategies for eliciting and synthesizing evidence for guidelines in rare diseases (2019) (29)
Haemophilia Experiences, Results and Opportunities (HERO) study: treatment‐related characteristics of the population (2015) (29)
Withdrawal of warfarin after deep vein thrombosis: effects of a low fixed dose on rebound thrombin generation. (1999) (28)
A critical appraisal of chronic kidney disease mineral and bone disorders clinical practice guidelines using the AGREE II instrument (2017) (28)
Concentrate‐related inhibitor risk: is a difference always real? (2011) (28)
Low-Molecular-Weight Heparin and Cancer Survival: Review of the Literature and Pooled Analysis of 1,726 Patients Treated for at Least Three Months (2003) (27)
Increased Plasma Levels of Tissue Factor Pathway Inhibitor (TFPI) after n-3 Polyunsaturated Fatty Acids Supplementation in Patients with Chronic Atherosclerotic Disease (1996) (27)
Individual participant data meta-analyses compared with meta-analyses based on aggregate data (2011) (26)
Reporting, handling and assessing the risk of bias associated with missing participant data in systematic reviews: a methodological survey (2015) (26)
Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA (2017) (26)
Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus. (2010) (26)
Applicability of the AGREE II instrument in evaluating the development process and quality of current National Academy of Clinical Biochemistry guidelines. (2012) (26)
Systematic reviews do not adequately report or address missing outcome data in their analyses: a methodological survey. (2018) (25)
Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences. (2020) (23)
Miconazole Oral Gel Potentiates Warfarin Anticoagulant Activity (2000) (23)
Cardiovascular disease (CVD) in Canadians with haemophilia: Age‐Related CVD in Haemophilia Epidemiological Research (ARCHER study) (2015) (23)
Care models in the management of haemophilia: a systematic review (2016) (23)
Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions (2015) (23)
Obtaining and managing data sets for individual participant data meta-analysis: scoping review and practical guide (2019) (23)
A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease. (2019) (22)
World Federation of Hemophilia Gene Therapy Registry (2020) (22)
Intracranial bleeding: epidemiology and relationships with antithrombotic treatment in 241 cerebral hemorrhages in Reggio Emilia. (2002) (22)
Developing methodology for the creation of clinical practice guidelines for rare diseases: A report from RARE-Bestpractices (2015) (22)
Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization (2019) (21)
Researching what matters to improve chronic pain care in Canada: A priority-setting partnership process to support patient-oriented research (2018) (21)
Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity (2014) (21)
Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS‐Hemo project (2020) (21)
Prophylaxis of venous thromboembolism in elderly patients with multimorbidity (2013) (21)
Individualizing Factor Replacement Therapy in Severe Hemophilia (2015) (21)
Pharmacokinetics of plasma‐derived vs. recombinant FVIII concentrates: a comparative study (2015) (21)
Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A (2019) (21)
Performance of recalibrated ReFacto® laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one‐stage assays after infusion of recalibrated ReFacto® (B‐domain deleted recombinant factor VIII) (2009) (21)
A systematic review of definitions and reporting of bleeding outcome measures in haemophilia (2015) (20)
Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction. (1995) (20)
Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol (2016) (20)
Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis (2017) (19)
Integrated multidisciplinary care for the management of chronic conditions in adults: an overview of reviews and an example of using indirect evidence to inform clinical practice recommendations in the field of rare diseases (2016) (19)
Selective outcome reporting: telling and detecting true lies. The state of the science (2010) (19)
Small intestinal bacterial overgrowth and warfarin dose requirement variability. (2010) (19)
Increasing the quantity and quality of searching for current best evidence to answer clinical questions: protocol and intervention design of the MacPLUS FS Factorial Randomized Controlled Trials (2014) (18)
Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy. (2011) (18)
Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH (2020) (18)
Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura (2020) (18)
The demographics, treatment characteristics and quality of life of adult people with haemophilia in China – results from the HERO study (2017) (18)
Risk-assessment models for VTE and bleeding in hospitalized medical patients: an overview of systematic reviews. (2020) (17)
Accuracy and Acceptability of Wrist-Wearable Activity-Tracking Devices: Systematic Review of the Literature (2021) (17)
Research and policy implications of a recently published controlled study in previously untreated haemophilia patients at high risk of inhibitor development (2017) (17)
Patient data meta‐analysis of Post‐Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF‐PFM (2014) (17)
Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. (2017) (17)
Impact of Adopting Population Pharmacokinetics for Tailoring Prophylaxis in Haemophilia A Patients: A Historically Controlled Observational Study (2019) (17)
Impact of missing participant data for dichotomous outcomes on pooled effect estimates in systematic reviews: a protocol for a methodological study (2014) (17)
Cardiovascular disease prevalence and relevance in haemophilia: a scoping review (2015) (17)
Inhibitor development in non-severe haemophilia across Europe (2015) (17)
Objectives and methodology: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). (2009) (17)
A methodological survey of the analysis, reporting and interpretation of Absolute Risk ReductiOn in systematic revieWs (ARROW): a study protocol (2013) (16)
Audit of the clinical use of fresh-frozen plasma in Umbria: study design and results of the pilot phase. (2008) (16)
Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B. (2014) (16)
Factor VIII products and inhibitors in severe hemophilia A. (2013) (16)
Successful treatment with rFVIIa of spontaneous intracerebral hemorrhage in a patient with mechanical prosthetic heart valves. (2005) (15)
Comparison of Disease Clusters in Two Elderly Populations Hospitalized in 2008 and 2010 (2013) (15)
Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup (2019) (15)
Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism. (2017) (15)
World bleeding disorders registry: The pilot study (2018) (15)
Prevalence and characteristics of antidepressant drug prescriptions in older Italian patients (2011) (15)
Shared topics on the experience of people with haemophilia living in the UK and the USA and the influence of individual and contextual variables: Results from the HERO qualitative study (2015) (15)
Non‐severe haemophilia: Is it benign? – Insights from the PROBE study (2020) (15)
Peginterferon Plus Ribavirin for Chronic Hepatitis C in Patients With Human Immunodeficiency Virus (2009) (15)
Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt‐PA for pulmonary embolism (1997) (15)
FVIII inhibitor development according to concentrate: data from the EUHASS registry excluding overlap with other studies (2016) (14)
High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance (2013) (14)
Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire (2017) (14)
Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A (2020) (14)
Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation. (2013) (14)
Point of care ultrasound in haemophilia: Building a strong foundation for clinical implementation (2017) (14)
Patient-level compared with study-level meta-analyses demonstrate consistency of D-dimer as predictor of venous thromboembolic recurrences. (2013) (14)
Comorbidities in persons with haemophilia aged 60 years or more compared with age‐matched people from the general population (2018) (14)
Methodology for the development of the NHF‐McMaster Guideline on Care Models for Haemophilia Management (2016) (13)
Influenza vaccination and vitamin K antagonist treatment: a placebo-controlled, randomized, double-blind crossover study. (2010) (13)
Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. (2010) (13)
McMaster Optimal Aging Portal: an evidence-based database for geriatrics-focused health professionals (2017) (13)
Developing a two‐sided intervention to facilitate shared decision‐making in haemophilia: decision boxes for clinicians and patient decision aids for patients (2014) (13)
Measuring the quality of haemophilia care across different settings: a set of performance indicators derived from demographics data (2017) (13)
Clinical trials and haemophilia: does the Bayesian approach make the ideal and desirable good friends? (2009) (13)
Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours (2015) (13)
Point of care ultrasonography in haemophilia care: recommendations for training and competency evaluation (2015) (13)
Test‐retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains (2018) (13)
Calculation of absolute risk for important outcomes in patients with and without a prognostic factor of interest. (2019) (13)
Mesenteric-portal Vein Thrombosis in a Patient with Hyperhomocysteinemia and Heterozygous for 20210A Prothrombin Allele (2000) (12)
Patient‐relevant health outcomes for hemophilia care: Development of an international standard outcomes set (2021) (12)
What is the role for population pharmacokinetics in hemophilia (2017) (12)
Development of haemophilic arthropathy of the ankle: results of a Delphi consensus survey on potential contributory factors (2015) (12)
Management of Patients With Unprovoked Venous Thromboembolism: An Evidence-Based and Practical Approach (2013) (12)
Focusing in on use of pharmacokinetic profiles in routine hemophilia care (2018) (12)
Psychological interventions for people with hemophilia. (2012) (12)
Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes (2020) (11)
Switching patients in the age of long-acting recombinant products? (2019) (11)
Recommended Primary Outcomes for Clinical Trials Evaluating Hemostatic Blood Products and Agents in Patients with Bleeding: Proceedings of a National Heart Lung and Blood Institute and United States Department of Defense Consensus Conference. (2021) (11)
Large scale studies assessing anti‐factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more (2017) (11)
Pharmacokinetic Optimisation of the Treatment of Deep Vein Thrombosis (1997) (11)
Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach (2019) (11)
Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review (2019) (11)
The association between platelet transfusions and mortality in patients with critical illness (2019) (11)
Healthcare provider knowledge, attitudes, beliefs, and practices surrounding the prescription of opioids for chronic non-cancer pain in North America: protocol for a mixed-method systematic review (2018) (11)
Patterns of tertiary prophylaxis in Canadian adults with severe and moderately severe haemophilia B (2014) (11)
Minimal dataset for post‐registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH (2017) (10)
Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type1 diabetic patients (2007) (10)
GRADE Guidelines 34: Updated GRADE guidance for imprecision rating using a minimally contextualized approach. (2022) (10)
Exploring regional variations in the cross‐cultural, international implementation of the Patient Reported Outcomes Burdens and Experience (PROBE) study (2019) (10)
User Experiences of the McMaster Optimal Aging Portal’s Evidence Summaries and Blog Posts: Usability Study (2016) (10)
Emicizumab state‐of‐the‐art update (2022) (10)
Dermatan sulphate in heparin-induced thrombocytopenia (1994) (10)
Joint Bleeding Tendencies in Adult Patients With Hemophilia: It’s Not All Pharmacokinetics (2019) (10)
An individual participant data meta-analysis of 13 randomized trials to evaluate the impact of prophylactic use of heparin in oncological patients (2017) (10)
Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. (2020) (9)
Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients (2019) (9)
If You Build It, Who Will Come? A Description of User Characteristics and Experiences With the McMaster Optimal Aging Portal (2017) (9)
Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series (2017) (9)
Prescriber adherence to guidelines for chronic noncancer pain management with opioids: Systematic review and meta-analysis. (2020) (9)
Prevention of venous thromboembolism after major orthopedic surgery: summing up evidence about old and new antithrombotic agents (2004) (9)
Risk models for VTE and bleeding in medical inpatients: systematic identification and expert assessment. (2020) (9)
Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A. (2015) (9)
Fibrinogen Degradation Products Generation is the Major Determinant of Platelet Inhibition Induced by Plasminogen Activators in Platelet-rich Plasma (1993) (9)
Understanding stakeholder important outcomes and perceptions of equity, acceptability and feasibility of a care model for haemophilia management in the US: a qualitative study (2016) (9)
A systematic review of using and reporting survival analyses in acute lymphoblastic leukemia literature (2016) (9)
A taxonomy and framework for identifying and developing actionable statements in guidelines suggests avoiding informal recommendations. (2021) (9)
The haemophilia certification system in Canada. (2014) (9)
Prehospital fresh frozen plasma: Universal life saver or treatment in search of a target population? (2018) (9)
Performance comparison of three assay methods used in fasting and postmethionine load plasma homocysteine determinations from patients with vascular disease. (2005) (9)
Different mechanisms regulate phosphatidylserine synthesis in rat cerebral cortex (1997) (8)
Impact of Persistent Antiphospholipid Antibodies on Symptomatic Thromboembolism In Children: A Systematic Review & Meta-Analysis [Observational Studies] (2010) (8)
Risk Factors for High-Titer Inhibitor Development in Children with Hemophilia A: Results of a Cohort Study (2013) (8)
Terminal half‐life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database (2021) (8)
Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption (2017) (8)
Shared topics on the experience of people with haemophilia living in the UK and the USA and the influence of individual and contextual variables: Results from the HERO qualitative study (2015) (8)
Epidemiology of Inhibitors in Hemophilia (2014) (8)
The Khorana Score for the prediction of venous thromboembolism in patients with solid cancer: An individual patient data meta-analysis (2017) (7)
Joint WFH‐ISTH session: issues in clinical trial design (2014) (7)
Interventions to Influence Opioid Prescribing Practices for Chronic Noncancer Pain: A Systematic Review and Meta-Analysis. (2020) (7)
Thrombophilia and cerebral vein thrombosis. (2008) (7)
Perioperative Management for Congenital Factor XI Deficiency; A Systematic Review (2016) (7)
Multicentre pharmacokinetic evaluation of rFVIII‐Fc (efmoroctocog alfa) in a real life and comparison with non‐extended half‐life FVIII concentrates (2020) (7)
Overall prognosis of preschool autism spectrum disorder diagnoses. (2017) (7)
Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age‐matched controls (2018) (6)
First analysis of 10-year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System (2014) (6)
Factor product utilization and health outcomes in patients with haemophilia A and B on extended half‐life concentrates: A Canadian observational study of real‐world outcomes (2021) (6)
Point‐of‐care ultrasonography in haemophilia care: Training and competency for muscular haematomas (2018) (6)
Clinical application of Web Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS‐Hemo): Patterns of blood sampling and patient characteristics among clinician users (2019) (6)
Bayesian approach to the assessment of the population-specific risk of inhibitors in hemophilia A patients: a case study (2016) (6)
Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study (2021) (6)
Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH (2016) (6)
The association between venous thromboembolism and physical inactivity in everyday life (2011) (6)
Safety and efficacy of ximelagatran: meta-analysis of the controlled randomized trials for the prophylaxis or treatment of venous thromboembolism. (2005) (6)
Haemophilia in a real‐world setting: the value of clinical experience in data collection (2016) (6)
Experimental evidences on the role of silica nanoparticles surface morphology on the loading, release and activity of three proteins (2019) (6)
Systematic reviews of prognosis studies: a critical appraisal of five core clinical journals (2017) (5)
Interpreting trial sequential analysis (2016) (5)
Switching to Warfarin after 6-Month Completion of Anticoagulant Treatment for Cancer-Associated Thrombosis (2015) (5)
Validating the "FACE" instrument using stakeholder perceptions of Feasibility, Acceptability, Cost and Equity in guideline implementation. (2020) (5)
Venous Thromboembolism Recurrence after a First Episode of Provoked Venous Thrombosis Due to a Transient Risk Factor. A Systematic Review of the Literature (2008) (5)
Plasma thrombin neutralization assay: pharmacokinetic applications. (1994) (5)
Computer-Aided Systematic Review Screening Comes of Age (2017) (5)
Context and Approach in Reporting Evaluations of Electronic Health Record–Based Implementation Projects (2020) (5)
GRADE Guidance article 35: Update on rating imprecision for assessing contextualized certainty of evidence and making decisions. (2022) (5)
Predicting Disease Recurrence in Patients with Previous Unprovoked Venous Thromboembolism: The DASH Prediction Score (2011) (5)
Machine Learning Approaches to Retrieve High-Quality, Clinically Relevant Evidence From the Biomedical Literature: Systematic Review (2021) (5)
The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A. (2018) (4)
GRADE concept paper 2: Concepts for Judging Certainty on the Calibration of Prognostic Models in a Body of Validation Studies. (2021) (4)
Impact of thrombophilia on arterial ischemic stroke or cerebral venous sinus thromboses in children: a systematic review & meta-analysis of observational studies (2010) (4)
Residual vein thrombosis and D-dimer for optimizing duration of anticoagulation in idiopathic deep vein thrombosis. (2010) (4)
Oral contraceptive use is a provoking factor for venous thromboembolism (2017) (4)
Risk factors for bleeding in people living with hemophilia A and B treated with regular prophylaxis: A systematic review of the literature (2022) (4)
Correction: A methodological survey of the analysis, reporting and interpretation of Absolute Risk ReductiOn in systematic revieWs (ARROW): a study protocol (2013) (4)
Development and application of health outcome descriptors facilitated decision-making in the production of practice guidelines. (2021) (4)
Evaluation of safety and effectiveness of factor VIII treatment in haemophilia A patients with low titre inhibitors or a personal history of inhibitor (2015) (4)
New methods facilitated the process of prioritizing questions and health outcomes in guideline development (2021) (4)
How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines (2021) (4)
Optimizing a literature surveillance strategy to retrieve sound overall prognosis and risk assessment model papers (2021) (3)
Predictors of treatment adherence in patients with chronic disease using the Multidimensional Adherence Model: unique considerations for patients with haemophilia (2020) (3)
Tools for Identifying Reliable Evidence and Implementing it in Everyday Clinical Care (2013) (3)
Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products (2021) (3)
The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B (2021) (3)
Recombinant Factor VIIa Concentrate versus Plasma-derived Concentrates for the Treatment of Acute Bleeding Episodes in Persons with Haemophilia and Inhibitors (2011) (3)
Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B. (2021) (3)
Successful treatment of Dieulafoy's disease in a von Willebrand patient. (2002) (3)
Non-Anticoagulant Actions of Glycosaminoglycans (1996) (3)
A Deep Learning Approach to Refine the Identification of High-Quality Clinical Research Articles From the Biomedical Literature: Protocol for Algorithm Development and Validation (2021) (3)
The D-dimer (DD) test to establish the duration of anticoagulation after a first unprovoked episod of venous thromboembolism (VTE); the prospective randomized “Prolong” Study on behalf of the Italian Federation of Anticoagulation Clinics (FCSA) (2005) (3)
Knowledge translation strategies for sharing evidence-based health information with older adults and their caregivers: findings from a persona-scenario method (2021) (3)
Comparisons of Factor Consumption for Routine Prophylaxis And Bleeding During Episodic Therapy With Recombinant Factor Viii Fc Fusion Protein and Conventional Recombinant Factor Viii. (2015) (3)
Effect of dermatan sulphate on activated partial thromboplastin time determined with different reagents. (1997) (3)
Good or best practice statements: proposal for the operationalisation and implementation of GRADE guidance (2022) (3)
Choice of End-points in Assessing the Efficacy of Post-discharge Prophylaxis for Venous Thromboembolism (1998) (3)
Deep Learning Method to Automatically Identify Reports of Scientifically Rigorous Clinical Research from the Biomedical Literature (2018) (3)
Prophylaxis of venous thromboembolism in elderly patients with multimorbidity Maura MarcucciAlfonso IorioAlessandro NobiliMauro TettamantiLuca PasinaCodjo Djignefa Djade • Alessandra MarengoniFrancesco SalernoSalvatore CorraoPier Mannuccio Mannucci • REPOSI (REgistro POliterapie SocietaItaliana di M (2013) (3)
Home therapy for inherited bleeding disorders in South Africa: Results of a modified Delphi consensus process. (2019) (2)
Heart failure and chronic kidney disease in a registry of internal medicine wards (2014) (2)
Tolerance to FVIII: Role of the Immune Metabolic Enzymes Indoleamine 2,3 Dyoxigenase-1 and Heme Oxygenase-1 (2020) (2)
Serine base exchange enzyme in porcine lyophilised platelets: enzyme properties and modulation by AIF4-and different types of heparin (2004) (2)
Protocol for a scoping review of outcomes in clinical studies of interventions for venous thromboembolism in adults (2020) (2)
RANDOMISED, OPEN, PROSPECTIVE, MULTICENTER PILOT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ACTIVATED RECOMBINANT FACTOR VIIA (NOVOSEVEN) IN ACUTE INTRACEREBRAL HAEMORRHAGE IN PATIENTS TREATED WITH ORAL ANTICOAGULANT OR ANTIPLATELET AGENTS (2007) (2)
Ruling out DVT using the Wells rule and a D-dimer test (2014) (2)
Are placebo‐controlled trials ethical in areas where current guidelines recommend therapy? No (2006) (2)
Seizures, headache and thrombocytopenia: diagnosis and treatment do not always come in a standard sequence (2007) (2)
Table of Contents (2011) (2)
Which actionable statements qualify as good practice statements In Covid-19 guidelines? A systematic appraisal (2022) (2)
Development and internal validation of a clinical prediction model for the diagnosis of immune thrombocytopenia (2022) (2)
Can evidence harm? Certainly not hemophilia treatment and community (2006) (2)
Haemophilia at various stages of life: design of new therapeutic strategies through an interactive course--the Kogeniale project. (2013) (2)
Second International Stroke Summit (2006) (2)
Individual participant datameta-analyses compared with meta-analyses based on aggregate data (Review) (2016) (2)
A personalized limited sampling approach to better estimate terminal half‐life of FVIII concentrates (2022) (2)
Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders (2021) (2)
Observational Study of Real-World Factor Utilization and Health Outcomes in Patients with Hemophilia in Canada (2018) (2)
Factor Consumption for Prophylaxis and Treatment of Bleeding: Recombinant Factor Ix Fc Fusion Protein Compared With Conventional Recombinant Factor Ix. (2015) (2)
A comparison of methods for prediction of pharmacokinetics across factor concentrate switching in hemophilia patients. (2019) (2)
Evaluation of the sexual health in people living with hemophilia (2021) (2)
Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company (2020) (2)
The current state of adverse event reporting in hemophilia (2017) (1)
Clinical efficacy and safety of moroctocog alfa (2011) (1)
The Effect of Platelet Transfusion on Death in the Intensive Care Unit (2016) (1)
Sexual Health in Patients with Hemophilia; The Insights from the Patient Reported Outcomes, Burdens and Experiences (PROBE) Study (2017) (1)
Systematic Review of the Published Evidence on the Pharmacokinetic Characteristics of Factor VIII and IX Concentrates (2014) (1)
Reflections on the Canadian Bleeding Disorders Registry: Lessons Learned and Future Perspectives (2022) (1)
User-centered development and testing of the online PROBE survey and the myPROBE app and integration with the Canadian bleeding disorder registry. (Preprint) (2021) (1)
An evaluation of the COVID-19 recommendation map identified diverging clinical and public health guidance (2022) (1)
Comparison of single subject and population‐based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A (2021) (1)
Women and Money in Australia: Across the Generations (2016) (1)
Exploring some intersections between pharmacokinetics, factor VIII measurement and human morphometrics – impact of recent advances in haemophilia study design on our understanding of optimal haemophilia treatment (2017) (1)
Clinical audit of the use of fresh frozen plasma in Umbria: study design and results of the pilot phase. (2008) (1)
Translating Clinical Questions by Physicians Into Searchable Queries: Analytical Survey Study (2020) (1)
Analysis of Hemophilia a Outcomes and Treatment Patterns Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry (2020) (1)
Impact of Thrombophilia On Arterial Ischemic Stroke or Cerebral Venous Sinus Thromboses in Children: A Systematic Review & Meta-Analysis of Observational Studies. (2009) (1)
Modeling The Impact of Potential Differences In Real-Wolrd Adherence With Extended-Half-Life Vs. Conventional Factor Viii And Ix on Bleeding. (2015) (1)
von Willebrand Factor-binding aptamer rondoraptivon pegol as treatment for severe and non-severe hemophilia A. (2022) (1)
Comparative Assessment of the Performance of Pharmacokinetic Tools for Prophylactic Dosing of Antihemophilic Factor Recombinant Plasma/Albumin-Free Method (rAHF-PFM) Concentrate in Patients with Hemophilia A (2017) (1)
Perioperative Management of Von Willebrand Disease, a Systematic Review and Meta-Analysis (2016) (1)
Indoleamine 2,3-Dioxygenase and Peripheral Tolerance to Exogenous Factor VIII: A Multi-Centre Pilot Study (2011) (1)
Developing a Two-Sided Intervention To Facilitate Shared Decision Making In Haemophilia: Decision Boxes For Clinicians and Brief Patient Decision Aids For Patients (2013) (1)
A decisional model to individualize warfarin recommendations: Expected impact on treatment and outcome rates in a real-world population with atrial fibrillation. (2016) (1)
Methodological considerations for investigating oral anticoagulation persistence in atrial fibrillation (2020) (1)
Risk difference estimation and reporting in systematic reviews. (2012) (1)
Inhibitor development in previously treated Haemophilia A patients: a systematic review, (2013) (1)
THU0561 Clinical practice guideline for diagnosis and management of catastrophic antiphospholipid syndrome (2017) (1)
Iatrogenic causes of an ICH: OAT therapy (2008) (1)
Extended reporting guidance for vaccine effectiveness studies for variants of concern for COVID-19 (2022) (1)
Hemophilia Experiences, Results and Opportunities (HERO) Study: US Respondent Demographics and Impact of Diagnosis On Career and Lifestyle Decisions and Quality of Life (2012) (1)
Comparison of quality of life, and emotional and functional profiles in older people with and without severe haemophilia (2021) (1)
Rate of inhibitor development in previously-untreated hemophilia A patients treated with plasma derived or recombinant factor VIII concentrates. A systematic review of the literature and meta-analysis (2010) (1)
Switching from standard to extended half‐life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics (2022) (1)
Correction to: Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients (2019) (1)
Indirect Comparison Of The Efficacy Of Recombinant Factor Viii Fc Fusion Protein And Other Factor Viii Products For ProphylaxisModeling The Effect Of Compliance (2014) (1)
Converting factor and nonfactor usage into a single metric to facilitate benchmarking the resources consumed for haemophilia care across jurisdictions and over time (2021) (1)
Knowledge translation strategies for sharing evidence-based health information with older adults and their caregivers: Findings from a co-design study (2021) (1)
Target plasma factor levels for personalized treatment in hämophilia: a Delphi consensus statement (2017) (1)
Low-Molecular-Weight and Unfractionated Heparin for Prevention of Venous Thromboembolism in Neurosurgery (2016) (1)
Determinants of inhibitor development in previously treated hemophilia A patients (2015) (1)
Desmopressin acetate (DDAVP) for preventing and treating bleeding in people with mild or moderate haemophilia A (2015) (1)
Indirect Comparison Of The Efficacy Of Recombinant Factor Ix Fc Fusion Protein And Other Factor Ix Products For Prophylaxis: Simulating The Effect Of Compliance On Real-World Effectiveness (2014) (1)
Translating Clinical Questions by Physicians Into Searchable Queries: Analytical Survey Study (Preprint) (2019) (1)
Correlations between von Willebrand Factor Antigen Levels and Factor VIII Pharmacokinetics Are Similar across Different FVIII Products in Patients with Severe Hemophilia A (2019) (1)
Selecting references that match constructs: the difficult job of citing the parachute hyperbole (2008) (1)
von Willebrand factor propeptide variants lead to impaired storage and ER retention in patient‐derived endothelial colony‐forming cells (2022) (1)
NON-ANTICOAGULANT ACTIONS OF GLYCOSAMINOGLYCANS Protein Binding Studies (1996) (1)
Clinical Study Risk Factors for High-Titer Inhibitor Development in Children with Hemophilia A : Results of a Cohort Study (2014) (1)
Clinical and Biological Determinants of Bleeding Manifestation in Congenital Factor XI Deficiency; A Systematic Review (2016) (1)
Hemophilia Impacts Quality of Life (QoL) in Adult PWH at an Early Age, with Pain a Contributing Factor: US Results From the Hemophilia Experiences, Results and Opportunities (HERO) Study (2012) (1)
Applied pharmacoeconomics: considerations to drive the choice of a prophylactic antithrombotic regimen (2003) (1)
A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients. (2020) (1)
WEB BASED SUPPORT FOR HAEMOPHILIA MANAGEMENT: AN INTER-REGIONAL NETWORK IN MIDDLE ITALY. (2008) (0)
PP93 HTA Role In CoreHEM, A Multi-Stakeholder Core Outcome Set Project (2018) (0)
Clinical Efficacy and Safety Versus Biological Response of Desmopressin (DDAVP) In Inherited Von Willebrand Disease (VWD) Types 1 and 2: Initial Results From the International Study Group on DDAVP In VWD In a Cohort of 229 Patients (2010) (0)
An evidence rating service provided valid correlates of the clinical importance of medical articles and journals. (2019) (0)
Associations between negative impact on employment or relationships and haemophilia treatment centre (HTC) and health care practioner utilisation: Global results from the haemophilia experiences, results and opportunities (HERO) study (2013) (0)
Test-Retest Reliability Analysis of the Patient Reported Outcomes Burdens and Experiences (PROBE) (2016) (0)
More about optimal choices in cardioembolism prevention (2011) (0)
Prevalence of potentially inappropriate medications in a cohort of hospitalized elderly: Results from the REPOSI study (2013) (0)
First Steps in Choosing Appropriate Instruments/Measurements for a Core Outcome Set: An Example from Corehem (2018) (0)
Emicizumab Outcomes in Hemophilia A Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry (2021) (0)
Real-World Outcomes of Emicizumab in Hemophilia A with or without FVIII Inhibitors from the Canadian Hemophilia Bleeding Disorder Registry (2022) (0)
Burden of Comorbid Diseases in Patients with Hemophilia: The Cross-Sectional Analysis of the Patient Reported Outcomes, Burden and Experiences (PROBE) Study (2017) (0)
Serine base-eschange enzyme in commercially available porcine lyophilized platelets: different effect of unfractionated and low molecular weight heparin (1999) (0)
do bleed rates and haemophilia treatment centre/provider utilisation vary with physical activity risk in adults with haemophilia: An analysis from the Hero study : Po 127 (2013) (0)
A Systematic Review of Definitions and Reporting of Bleeding Outcome Measures in Hemophilia (2014) (0)
Meta-Analysis of Observational Studies Sinovenous Thrombosis in Neonates and Children. A Systematic Review and Impact of Thrombophilia on Risk of Arterial Ischemic Stroke or Cerebral (2011) (0)
External qualification of the Web‐Accessible Population Pharmacokinetic Service–Hemophilia (WAPPS‐Hemo) models for octocog alfa using real patient data (2021) (0)
2 coagulation disorders factor VIII and IX deficiency: an index of different clinical severity of the Comparison of the rates of joint arthroplasty in patients with severe (2013) (0)
Potency-Adjusted Analyses of a Head-to-Head Pharmacokinetic Study of Damoctocog Alfa Pegol (BAY 94-9027) and Efmoroctocog Alfa (rFVIIIFc) in Patients with Severe Hemophilia A (2020) (0)
Driving ahead with one eye on the rear view mirror What ’ s the future of Physiotherapy in Haemophilia care ? (2018) (0)
Driving ahead with one eye on the rear view mirror What ’ s the future of Physiotherapy in Haemophilia care ? (2018) (0)
Venous thrombotic risk assessment among factor V Leiden carriers undergone a thrombophilic screening by different types of indications (2004) (0)
Not All Patients Benefit from Switching to Ehl: Results from the Wapps Database (2020) (0)
Cost‐utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada (2022) (0)
Associations between inhibitors, treatment regimen, and bleed frequency and health care practitioner utilisation in the haemophilia treatment centre (HTC): Global results from the haemophilia experiences, results and opportunities (HERO) study (2013) (0)
Fresh Frozen Plasma Transfusion Practice: A Regional Benchmark Study. (2009) (0)
Oral anticoagulant therapy with POC device and remote computer monitoring in the setting of the Italian National Health System (INHS) (2003) (0)
Review: Perioperative LMW heparin does not reduce mortality after surgery more than unfractionated heparin in patients with cancer (2008) (0)
The Wells rule and a primary care rule were useful for ruling out deep venous thrombosis in primary care (2011) (0)
High Efficacy of Combination Therapy with Pegylated Interferon and Ribavirin in Hemophiliacs with Chronic Hepatitis C. (2005) (0)
Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study (2022) (0)
PROSPECTIVE ASSESSMENT OF CLINICAL ENDPOINTS OF VKA TREATMENT IN A PRIMARY CARE COMPUTER ASSISTED MANAGEMENT MODEL (2007) (0)
Clinical validation of a new algorithm for computerized dosing of vitamin K antagonist therapy: a retrospective simulation study (2013) (0)
Routine Double Filtration Plasmapheresis Affects Hemostatic Proteins and Prolongs Clotting Tests (2019) (0)
Erratum to “Small intestinal bacterial overgrowth and warfarin dose requirement variability” [Thromb. Res. 126 (1) (2010) 12–17] (2013) (0)
Theoretical Foundation for Research in Communication using Information and Communication Technology Devices in Healthcare: An Interdisciplinary Scoping Review (2013) (0)
Prothrombotic risk factors in patients with ischaemic stroke or tia under age 50 (2000) (0)
Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia (2022) (0)
Low-molecular-weight-heparin treatment and cancer: pooled analysis of 908 patients treated for three months and review of the literature (2002) (0)
A 9-factor score predicted 2-year risk for bleeding in outpatients with, or at high risk for, atherothrombosis (2010) (0)
Terminal Half-Life of Factor VIII/IX According to Age and Blood Group Based on 8550 Assessments (2020) (0)
Response: Comparing joint arthroplasties in severe hemophilia A with severe hemophilia B (2009) (0)
Ten-Year Canadian National Prospective Data On Utilization of Anti-Hemophilic Concentrates: Indications and Trends (2012) (0)
Summarizing the theoretical foundation for hospital communication research: A scoping review of interdisciplinary literature. (2012) (0)
Thrombosis in congenital a-, dys- and hypofibrinogenemia (2017) (0)
Systematic Review of Randomized Controlled Trials of Prophylactic Clotting Factor Concentrate in Hemophilia. (2005) (0)
Assessment of Recurrence Risk After Unprovoked Venous Thromboembolism (2011) (0)
Low-molecular-weight heparin treatment and cancer: pooled analysis of 908 patients treated for three months (2002) (0)
EffectivenessofComputerizedDecisionSupportSystems LinkedtoElectronicHealthRecords:ASystematicReview (2014) (0)
Absence of Interaction Between Influenza Vaccination and Oral Anticoagulant Therapy: A Randomized Blinded Clinical Trial (2005) (0)
Plasma homocysteine measurement: comparison of three different assay methods in plasma from vascular patients (1999) (0)
Elderly patients treated with oral anticoagulant: a prospective cohort study (1999) (0)
Derivation of a Pharmacokinetic Model to Include a Plasma-Derived, von Willebrand Factor-Containing Factor VIII (Koate®-DVI) Concentrate and its Low-Dose Use (2021) (0)
Perioperative Outcomes Associated with Inhibitor Status in Patients with Hemophilia - a Retrospective Cohort Study (2021) (0)
Prospective Study of the Immunological Mechanisms of Immune Tolerance Induction in Severe Haemophilia a Patients with Inhibitors: Preliminary Analysis of a Multi-Center Longitudinal Study (2018) (0)
Warfarin Resumption after Intracranial Hemorrhage: A Systematic Review and Meta-Analysis (2016) (0)
OAT with POC devices and remote computer monitoring in the setting of the Italian NHS: a controlled clinical trial (2004) (0)
Haemophilia clinical care and research needs: Assessing priorities (2018) (0)
Understanding intravenous iron ordering practices for inpatients and outpatients at a large academic institution (2016) (0)
Bleeding in Patients Receiving Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis (2015) (0)
Sexual issues in people with haemophilia: Awareness and strategies for overcoming communication barriers (2021) (0)
Interim Canadian Data from a Prospective, Observational Study of Routine Clinical Use of a Von Willebrand Factor Concentrate (Wilate®) (2016) (0)
Utilization of a surgical database to provide care and assess perioperative treatment and outcomes in patients with bleeding disorders (2021) (0)
Post-discharge deep-vein thrombosis after orthopaedic surgery (1996) (0)
Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature. (2009) (0)
Pharmacokinetics of the reformulated B-domain deleted recombinant factor VIII concentrate using chromogenicand one-stage assays with pooled normal plasma and refacto laboratory standard (2007) (0)
Corrigendum (1995) (0)
Prothrombin 202120A mutation in Behcet’s disease (1999) (0)
Venous thromboembolism prophylaxis in elderly patients admitted to Italian internal medicine wards (2013) (0)
Validation and Updating of a Prognostic Survival Model The Vienna Prediction Model (2013) (0)
A Predictive Model for the Development of High-Responding Inhibitor In Children with Severe and Moderate Hemophilia A- Results of a Multicenter Cohort Study (2010) (0)
Safety and Effectiveness of Desmopressin for the Management of Delivery and Major Surgery in Patients with Mild-Moderate Von Willebrand Disease: Final Analysis of the Prodeswil Study (2015) (0)
Creating a Population Model for PK-Tailored Dosing Using Real-World Data from the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) Platform (2018) (0)
Clinical efficacy and safety of DDAVP with or without tranexamic acid in inherited VWD: final results of the prospective and international study on 229 patients (2013) (0)
User-centered development and testing of the online PROBE survey and the myPROBE app, and integration with the Canadian bleeding disorder registry. (Preprint) (2021) (0)
Inhibition of fluid phase and fibrin bound thrombin: effect of heparin, r-hirudin, PEG-rm-hirudin and a thrombin exosite inhibitor (2000) (0)
[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. (2019) (0)
Low-molecular-weight heparin and cancer survival: pooled analysis of 1726 patients treated for three months (2004) (0)
Prevalence and Determinants of Bleeding in Severe Von Willebrand Disease Type 3: Results of Retro/Prospective Studies in a Cohort of 105/52 Italian Patients. (2009) (0)
Does higher risk activity change bleed frequency and haemophilia treatment center/provider utilisation in children with haemophilia: an analysis from the HERO study (2013) (0)
Installing FVIII-Specific Tolerance in Hemophilia Via Engagement of the Aryl Hydrocarbon Receptor By Tryptophan Derivatives (2016) (0)
Thrombotic risk and laboratory pattern 91 consecutive patients with lupus anticoagulant and/or anticardiolipin antibodies (2001) (0)
Answering relevant research questions via careful observation of clinical practice: a fresh look at the old way forward (2014) (0)
Prophylaxis use of clotting factor replacement products in people with non‐severe haemophilia: A review of the literature (2022) (0)
Thrombolytic and haemorrhagic effects of bolus doses of rt-PA and A hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935) (1992) (0)
Machine Learning Approaches to Retrieve High-Quality, Clinically Relevant Evidence From the Biomedical Literature: Systematic Review (Preprint) (2021) (0)
PROSPECTIVE STUDY OF THE IMMUNOLOGICAL MECHANISMS OF IMMUNE TOLERANCE INDUCTION IN HAEMOPHILIA A PATIENTS WITH INHIBITORS (2017) (0)
Evaluation of Plasma-Derived FVII Efficacy for the Treatment of Bleeding in a Murine Model of Hemophilia a (2017) (0)
Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization (2019) (0)
VP57 Test-Retest Reliability Analysis Of The Patient Reported Outcomes Burdens And Experiences (PROBE) Study Questionnaire Test-Retest Reliability Analysis Of The PROBE Study Questionnaire (2017) (0)
The effect of influenza vaccination in patients on long-term oral anticoagulant therapy (2006) (0)
Efficacy of influenza vaccination in elderly persons on long-term oral anticoagulation therapy (2006) (0)
The landscape of strongholds (2016) (0)
Auto Machine Learning Approaches to Refine the Identification of High-Quality Clinical Research Articles from The Biomedical Literature: A Study Protocol (Preprint) (2021) (0)
Recommendations and guidelines for creating scholarly biomedical journals: A scoping review (2023) (0)
User-Centered Development and Testing of the Online Patient-Reported Outcomes, Burdens, and Experiences (PROBE) Survey and the myPROBE App and Integration With the Canadian Bleeding Disorder Registry: Mixed Methods Study (2022) (0)
GRADE Guidance 36: Updates to GRADE's approach to addressing inconsistency. (2023) (0)
Accuracy and Acceptability of Wrist-Wearable Activity Tracking Devices: A Systematic Review of the Literature. (Preprint) (2021) (0)
Correction to: Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients (2019) (0)
Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes. (2023) (0)
Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients (2019) (0)
Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: A scoping review (2022) (0)
Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products (2019) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Alfonso Iorio?

Alfonso Iorio is affiliated with the following schools:

University of British Columbia
University of Perugia
McMaster University
University of Colorado

Alfonso Iorio's Academic­Influence.com Rankings

Why Is Alfonso Iorio Influential?

Alfonso Iorio's Published Works

Published Works

What Schools Are Affiliated With Alfonso Iorio?

Alfonso Iorio's AcademicInfluence.com Rankings